The company's pipeline of monoclonal antibodies, including RYI-008, is developed using a series of technologies, such as the iCAP system, to target a select subset of G protein coupled receptors (GPCR) with specificity in binding that has proven difficult to achieve with small molecule modulators. Bird Rock Bio's antibodies leverage biological targets with substantial human proof of mechanism for the development of best-in-class therapeutic antibodies with significant clinical and commercial differentiation, making them ideal for immuno-inflammatory regulators for treatment.